A M Thompson1, T Rapson, F J Gilbert, K G M Park. 1. Department of Surgery and Molecular Oncology, University of Dundee, Ninewells Hospital and Medical School, DD1 9SY, Dundee, Scotland, United Kingdom. a.m.thompson@dundee.ac.uk
Abstract
BACKGROUND: Under the auspices of the Scottish Audit of Gastric and Esophageal Cancer, we investigated treatment techniques, complications, and survival in a population-based cohort of patients undergoing endoscopic palliative therapy for esophageal or gastric cancer. METHODS: A total of 948 patients undergoing endoscopic palliative therapy were identified prospectively and followed for a minimum of 1 year. RESULTS: Expandable metal stent placement (506 patients) and LASER (117 patients) were the most frequently used treatment options. Stent placement was more common for grade 3 or 4 dysphagia. Delivery of endoscopic palliative therapy varied by region of residence (from 18% to 38% of patients, p < 0.001) but not by deprivation category. Complications were recorded in 16% of patients (155 of 948). Overall survival was 40% (95% confidence interval [CI], 36-43) at 6 months, 17% (95% CI, 14-19) at 12 months, and 10% (95% CI, 8-12%) at 18 months. CONCLUSIONS: These data define the reality of endoscopic palliative therapy for patients with advanced esophageal or gastric cancer and provide a baseline against which future improvements in care can be measured.
BACKGROUND: Under the auspices of the Scottish Audit of Gastric and Esophageal Cancer, we investigated treatment techniques, complications, and survival in a population-based cohort of patients undergoing endoscopic palliative therapy for esophageal or gastric cancer. METHODS: A total of 948 patients undergoing endoscopic palliative therapy were identified prospectively and followed for a minimum of 1 year. RESULTS: Expandable metal stent placement (506 patients) and LASER (117 patients) were the most frequently used treatment options. Stent placement was more common for grade 3 or 4 dysphagia. Delivery of endoscopic palliative therapy varied by region of residence (from 18% to 38% of patients, p < 0.001) but not by deprivation category. Complications were recorded in 16% of patients (155 of 948). Overall survival was 40% (95% confidence interval [CI], 36-43) at 6 months, 17% (95% CI, 14-19) at 12 months, and 10% (95% CI, 8-12%) at 18 months. CONCLUSIONS: These data define the reality of endoscopic palliative therapy for patients with advanced esophageal or gastric cancer and provide a baseline against which future improvements in care can be measured.
Authors: L R Coia; B D Minsky; B A Berkey; M J John; D Haller; J Landry; T M Pisansky; C G Willett; J P Hoffman; J B Owen; G E Hanks Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544